In MS specifically, previous studies have shown that defective suppressive function of patients’ Tregs is associated with impaired Foxo1 signaling and increased IFN-γ (9, 10), and reversal of this impaired Foxo1 signaling restores Treg-suppressive activity (10). The gene discussed is FOXO1; the disease is myeloid sarcoma.